AGM, page-7

4. "Partnering agreement. And, if it’s the latter, whether to sign up pre or post Rett paediatric trial results."

'Our primary objective remains to progress the development of trofinetide as quickly as we can, while at the same time seeking to maximise the commercial value to Neuren and our shareholders.'

I would assume, given the recent TBI results, although not entirely inconclusive, entering a partnering agreement prior to the Rett results would satisfy both the primary objective and more importantly, 'protect'/maximise the commercial value to Neuren and its shareholders.